Li Yan, Huang Xin-En, Jin Guang-Fu, Shen Hong-Bin, Xu Lin
Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute, Nanjing, China.
Asian Pac J Cancer Prev. 2011;12(3):739-42.
To examine the association between genetic polymorphisms (at XRCC1codon 399 or XPD codon 751) and chemotherapy related toxicities of non-small cell lung cancer.
One hundred and fifteen patients with histologically or cytologically confirmed stage IIIB and IV NSCLC recruited from Department of Chemotherapy of Jiangsu Cancer Hospital and Research Institute from 2005 to 2008, to evaluated the occurrence of chemotherapy related toxicities and the association with single nucleotide polymorphisms in XRCC1codon 399 or XPD codon 751.
No significant association was observed between grade 0 or grade 1-4 overall toxicity and XRCC1 codon 399 (odds ratio=1.40, 95% confidence interval,0.73-2.66; adjusted odds ratio =1.43, 95% confidence interval,0.71-2.88), or XPD codon 751 genetic polymorphisms (odds ratio =0.87, 95% confidence interval,0.33-2.26; adjusted odds ratio=0.74, 95% confidence interval,0.26-2.13); similar results were found between hematologic, hepatic, gastrointestinal toxicities and XRCC1 399 or XPD 751 genetic polymorphisms.
No statistically significant association was found between either XRCC1codon 399 or XPD codon 751 genetic polymorphisms and chemotherapy related toxicities.
研究基因多态性（XRCC1基因第399密码子或XPD基因第751密码子）与非小细胞肺癌化疗相关毒性之间的关联。
2005年至2008年从江苏省肿瘤医院化疗科招募115例经组织学或细胞学确诊为IIIB期和IV期的非小细胞肺癌患者，评估化疗相关毒性的发生情况以及与XRCC1基因第399密码子或XPD基因第751密码子单核苷酸多态性的关联。
0级或1 - 4级总体毒性与XRCC1基因第399密码子（比值比 = 1.40，95%置信区间，0.73 - 2.66；校正比值比 = 1.43，95%置信区间，0.71 - 2.88）或XPD基因第751密码子基因多态性（比值比 = 0.87，95%置信区间，0.33 - 2.26；校正比值比 = 0.74，95%置信区间，0.26 - 2.13）之间未观察到显著关联；血液学、肝脏、胃肠道毒性与XRCC1第399密码子或XPD第751密码子基因多态性之间也得到类似结果。
未发现XRCC1基因第399密码子或XPD基因第751密码子基因多态性与化疗相关毒性之间存在统计学显著关联。
